About Verastem, Inc.
https://www.verastem.comVerastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.
CEO
Daniel W. Paterson
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-01 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 71
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
BTIG
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
B. Riley Securities
Buy
RBC Capital
Outperform
Mizuho
Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:5.43M
Value:$36.84M
BALYASNY ASSET MANAGEMENT L.P.
Shares:4.15M
Value:$28.16M
LOGOS GLOBAL MANAGEMENT LP
Shares:4.05M
Value:$27.5M
Summary
Showing Top 3 of 153
About Verastem, Inc.
https://www.verastem.comVerastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.24M ▲ | $50.29M ▲ | $-98.52M ▼ | -876.34% ▲ | $-1.35 ▼ | $-98.23M ▼ |
| Q2-2025 | $2.14M ▲ | $45.45M ▲ | $-25.93M ▲ | -1.21K% ▼ | $-0.39 ▲ | $-25.59M ▲ |
| Q1-2025 | $0 | $44.17M ▲ | $-52.1M ▲ | 0% | $-0.96 ▲ | $-51.9M ▲ |
| Q4-2024 | $0 | $31.59M ▼ | $-64.55M ▼ | 0% | $-1.7 ▼ | $-63.21M ▼ |
| Q3-2024 | $0 | $37.03M | $-23.97M | 0% | $-0.6 | $-22.81M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $137.71M ▼ | $176.85M ▼ | $192.38M ▲ | $-15.53M ▼ |
| Q2-2025 | $164.32M ▲ | $196.26M ▲ | $160.21M ▼ | $36.06M ▲ |
| Q1-2025 | $117.57M ▲ | $131.7M ▲ | $164.13M ▲ | $-32.43M ▼ |
| Q4-2024 | $88.82M ▼ | $101.54M ▼ | $130.43M ▲ | $-28.89M ▼ |
| Q3-2024 | $113.17M | $126.38M | $94.16M | $32.22M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-98.52M ▼ | $-36.22M ▼ | $-8.28M ▼ | $17.88M ▼ | $-26.62M ▼ | $-36.22M ▼ |
| Q2-2025 | $-25.93M ▲ | $-32.66M ▲ | $0 | $79.42M ▲ | $46.75M ▲ | $-32.66M ▲ |
| Q1-2025 | $-52.1M ▲ | $-38.68M ▼ | $0 | $67.43M ▲ | $28.75M ▲ | $-38.68M ▼ |
| Q4-2024 | $-64.55M ▼ | $-25.1M ▼ | $0 | $742K ▼ | $-24.36M ▼ | $-25.1M ▼ |
| Q3-2024 | $-23.97M | $-23.8M | $0 | $53.6M | $29.8M | $-23.8M |
Revenue by Products
| Product | Q3-2022 | Q4-2022 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Government rebates and other incentives | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Returns | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Trade discounts and allowances | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Sale of COPIKTRA license and related assets | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Daniel W. Paterson
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-01 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 71
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
BTIG
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
B. Riley Securities
Buy
RBC Capital
Outperform
Mizuho
Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:5.43M
Value:$36.84M
BALYASNY ASSET MANAGEMENT L.P.
Shares:4.15M
Value:$28.16M
LOGOS GLOBAL MANAGEMENT LP
Shares:4.05M
Value:$27.5M
Summary
Showing Top 3 of 153